Navigating the intricate landscape of legal acquisition for controlled substances, specifically Schedule I drugs, represents a particularly niche area for licensed Québécois institutions—typically scientific facilities—and demands meticulous adherence to stringent regulations. This process goes far beyond standard provider selection, encompas